Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL4652889

CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.O=P([O-])([O-])F.O=P([O-])([O-])F.O=P([O-])([O-])F.O=P([O-])([O-])F.O=P([O-])([O-])F.O=P([O-])([O-])F

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.60
SLC22A2 O15244 1/20 0.52
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DNM1 Q05193 5/20 0.44
LMNA P02545 1/20 0.41
ESR1 P03372 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CDC25A P30304 1/20 0.41
AGTR1 P30556 1/20 0.41
AKT1 P31749 1/20 0.41
ADRA1A P35348 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL10933481 1.00 SLC22A1 (0.60) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7800475 1.00 SLC22A1 (0.60) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL19834900 0.92 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL49814 0.92 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
SCHEMBL20543356 0.91 DNM1 (0.52) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL703752 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL31067882 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28547695 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3141779 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL28973535 0.90 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0244717-A2 Process for the preparation of 2,3-epoxyamides BAYER AG (DE) 1987-11-11 EP claimed
US-12172964-B2 Tricyclic octacationic cyclophane and its use in complexation with perlene diimide dyes NORTHWESTERN UNIVERSITY (US) 2024-12-24 US disclosed
US-20230250240-A1 POLYROTAXANES AND METHODS OF MAKING AND USING THE SAME UNIV NORTHWESTERN (US) 2023-08-10 US disclosed
US-11300555-B2 Methods of analyzing crude oil PURDUE RESEARCH FOUNDATION (US) 2022-04-12 US disclosed
US-20220048860-A1 TRICYCLIC OCTACATIONIC CYCLOPHANE AND ITS USE IN COMPLEXATION WITH PERLENE DIIMIDE DYES NORTHWESTERN UNIVERSITY 2022-02-17 US disclosed
EP-3567040-B1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC (US) 2020-09-09 EP disclosed
US-20200173976-A1 METHODS OF ANALYZING CRUDE OIL UNITED STATES DEPARTMENT OF ENERGY 2020-06-04 US disclosed
US-10600865-B2 Materials and methods for the preparation of nanocomposites THE UNIVERSITY OF CHICAGO (US) 2020-03-24 US disclosed
US-10571453-B2 Methods of analyzing crude oil PURDUE RESEARCH FOUNDATION (US) 2020-02-25 US disclosed
EP-3567040-A1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES Amgen, Inc (US) 2019-11-13 EP disclosed
US-20140346442-A1 MATERIALS AND METHODS FOR THE PREPARATION OF NANOCOMPOSITES THE UNIVERSITY OF CHICAGO (US) 2014-11-27 US disclosed
WO-2013102068-A1 CHEMILUMINESCENT SYSTEM MAGGILUME (US) 2013-07-04 WO disclosed
US-20130168620-A1 Chemiluminescent system Maggilume, LLC 2013-07-04 US disclosed
US-20120318679-A1 METHODS AND COMPOSITIONS COMPRISING MACROCYCLES, INCLUDING HALOGENATED MACROCYCLES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-12-20 US disclosed
WO-2012158847-A2 MATERIALS AND METHODS FOR THE PREPARATION OF NANOCOMPOSITES THE UNIVERSITY OF CHICAGO (US) 2012-11-22 WO disclosed
EP-1989447-A1 DEVICE FOR MOVING LIQUIDS AND/OR GASES Albert-Ludwigs-Universität Freiburg (DE) 2008-11-12 EP disclosed
WO-2008062316-A2 A SELF-MAINTAINED SENSOR USING A LOW POWER ACTUATOR DUBLIN CITY UNIVERSITY (IE) 2008-05-29 WO disclosed
WO-2007085434-A1 DEVICE FOR MOVING LIQUIDS AND/OR GASES ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2007-08-02 WO disclosed
EP-0416567-A2 Intrinsically electro-conductive polymers, process for preparing the same and use thereof HOECHST AKTIENGESELLSCHAFT (DE) 1991-03-13 EP disclosed
EP-0244717-A2 Process for the preparation of 2,3-epoxyamides BAYER AG (DE) 1987-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120318679-A1 METHODS AND COMPOSITIONS COMPRISING MACROCYCLES, INCLUDING HALOGENATED MACROCYCLES TERT, HCCS, POLL SLC22A1 4515/4885SLC22A2 4392/4885ALDH1A1 3443/4885
US-12172964-B2 Tricyclic octacationic cyclophane and its use in complexation with perlene diimide dyes PPIE, PORCN, PPIA SLC22A1 409/4885SLC22A2 340/4885ALDH1A1 1984/4885
US-20220048860-A1 TRICYCLIC OCTACATIONIC CYCLOPHANE AND ITS USE IN COMPLEXATION WITH PERLENE DIIMIDE DYES PPIE, PORCN, PPIA SLC22A1 409/4885SLC22A2 340/4885ALDH1A1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.